Clinical utility of a serum biomarker panel in distinguishing prostate cancer from benign prostate hyperplasia

Prostate-specific antigen (PSA) screening for prostate cancer (PCa) is limited by the lack of specificity but is further complicated in the benign prostatic hyperplasia (BPH) population which also exhibit elevated PSA, representing a clear unmet need to distinguish BPH from PCa. Herein, we evaluated...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Sci Rep
Main Authors: Kiebish, Michael A., Tekumalla, Poornima, Ravipaty, Shobha, Dobi, Albert, Srivastava, Shiv, Wu, Wenfang, Patil, Saurabh, Friss, Tracey, Klotz, Allison, Srinivasan, Alagarsamy, Cullen, Jennifer, Rosner, Inger L., Ali, Amina, Laszlo, Sandra, Petrovic, Michele, Fleshner, Neil, Garren, Jeonifer, Miller, Greg, Mahaveer Chand, Nischal, Rodrigues, Leonardo O., Granger, Elder, Kellogg, Mark D., Luan, Shen, Diamandis, Eleftherios, Akmaev, Viatcheslav R., Sarangarajan, Rangaprasad, Bountra, Chas, Freedland, Stephen J., McLeod, David G., Narain, Niven R.
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group UK 2021
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC8302659/
https://ncbi.nlm.nih.gov/pubmed/34302010
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-021-94438-4
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki